Literature DB >> 20482238

Treatment of refractory melasma with the MedLite C6 Q-switched Nd:YAG laser and alpha arbutin: a prospective study.

Niwat Polnikorn1.   

Abstract

OBJECTIVE: To evaluate the effectiveness of a Q-switched Nd:YAG laser (MedLite C6; HOYA ConBio, Fremont, CA, USA) and 7% alpha arbutin solution (Skin Advance Laboratory, Japan) in the treatment of melasma.
METHODS: This was a prospective study of 35 refractory melasma cases treated with 10 weekly laser sessions, two monthly follow-up treatments and topical 7% alpha arbutin solution. Clinical photographs and severity grading on a 5-point scale were carried out by an independent observer at each visit.
RESULTS: At 6 months, 30% of study subjects received results in the excellent clearance category (> 81% reduction of melasma) and 36.7% received good (51-80% reduction) clearance. Mild and transient side effects included discomfort during treatment, erythema, whitening of fine hair and urticaria. Three cases of mottling hypo-pigmentation (8.57%) and two cases of recurrence of melasma (5.71%) were recorded.
CONCLUSION: Combination therapy with the MedLite C6 and 7% alpha arbutin solution is an effective and well-tolerated treatment for refractory melasma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482238     DOI: 10.3109/14764172.2010.487910

Source DB:  PubMed          Journal:  J Cosmet Laser Ther        ISSN: 1476-4172            Impact factor:   2.247


  9 in total

1.  A split-face study: comparison of picosecond alexandrite laser and Q-switched Nd:YAG laser in the treatment of melasma in Asians.

Authors:  Mei-Ching Lee; Ying-Fang Lin; Sindy Hu; Yau-Li Huang; Shyue-Luen Chang; Chun-Yu Cheng; Chun-Shin Chang
Journal:  Lasers Med Sci       Date:  2018-05-07       Impact factor: 3.161

Review 2.  Are Natural Ingredients Effective in the Management of Hyperpigmentation? A Systematic Review.

Authors:  Jasmine C Hollinger; Kunal Angra; Rebat M Halder
Journal:  J Clin Aesthet Dermatol       Date:  2018-02-01

Review 3.  Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma.

Authors:  Douglas C Wu; Richard E Fitzpatrick; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

4.  Treatment of Melasma with the Photoacoustic Twin Pulse Mode of Low-Fluence 1,064 nm Q-Switched Nd:YAG Laser.

Authors:  Jee Young Kim; Misoo Choi; Chan Hee Nam; Ji Seok Kim; Myung Hwa Kim; Byung Cheol Park; Seung Phil Hong
Journal:  Ann Dermatol       Date:  2016-05-25       Impact factor: 1.444

5.  Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma.

Authors:  Nilendu Sarma; Sayantani Chakraborty; Shital A Poojary; Sanjay Rathi; Sendhil Kumaran; Balakrishnan Nirmal; Joan Felicita; Rashmi Sarkar; Prashansa Jaiswal; Paschal D'Souza; Nagaraju Donthula; Sumit Sethi; Pallavi Ailawadi; Bebisha Joseph
Journal:  Indian Dermatol Online J       Date:  2017 Nov-Dec

6.  Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group.

Authors:  Rashmi Sarkar; Narendra Gokhale; Kiran Godse; Pallavi Ailawadi; Latika Arya; Nilendu Sarma; R G Torsekar; V K Somani; Pooja Arora; Imran Majid; G Ravichandran; Mohan Singh; Sanjeev Aurangabadkar; Shehnaz Arsiwala; Sidharth Sonthalia; T Salim; Swapnil Shah
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

Review 7.  Laser treatment of medical skin disease in women.

Authors:  C LaRosa; A Chiaravalloti; S Jinna; W Berger; J Finch
Journal:  Int J Womens Dermatol       Date:  2017-07-21

Review 8.  The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review.

Authors:  Yeon Seok Lee; Yu Jin Lee; Jung Min Lee; Tae Young Han; June Hyunkyung Lee; Jae Eun Choi
Journal:  Medicina (Kaunas)       Date:  2022-07-14       Impact factor: 2.948

9.  Lasers for treatment of melasma and post-inflammatory hyperpigmentation.

Authors:  Pooja Arora; Rashmi Sarkar; Vijay K Garg; Latika Arya
Journal:  J Cutan Aesthet Surg       Date:  2012-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.